- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT02640495
Artemisinin Resistance In Malaria Treated With IV Artesunate (ARIMTIA)
A Multicenter, Prospective, Observational Study to Assess the Efficacy of Artesunate in Malaria Treated With Parenteral Artesunate in Areas With Artemisinin Resistance A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC)
The spread of artemisinin resistant falciparum malaria presents new challenges to both the control and treatment of malaria. Loss of ring stage susceptibility to the artemisinins might jeopardize the use of parenteral artesunate as the first line drug for the treatment of severe falciparum malaria.
The purpose of this study is to assess the effect of artemisinin resistance (defined by a Kelch13 mutation with known functional significance) in P. falciparum malaria requiring parenteral artesunate treatment on lactate clearance parameters.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
The investigators propose a multi-center observational study to assess the effect of artemisinin resistance (as defined by the presence of relevant Kelch13 mutations) on the efficacy of parenteral artesunate for the treatment of malaria, stratified for disease severity on admission.
The patients will receive the standard intravenous treatment for severe malaria (parenteral artesunate). Primary endpoints will be the plasma lactate concentration at 12 hours as a proportion of the plasma lactate at the start of treatment. Secondary endpoints will be improvement of Glasgow or Blantyre Coma Scores and other indicators of neurological recovery or deterioration, parasite clearance rates, time until resolution of fever, development of new severity or neurological signs under treatment, development of severe anemia, renal and hepatic injury, total duration of hospitalization , outcome of pregnancy in pregnant female patients, mortality rates and the necessity to treat with antibiotics, need for renal replacement therapy, mechanical ventilation, blood transfusion and rescue treatments.
On admission blood will be taken for the determination of genetic markers of antimalarial resistance (including Kelch13 mutations of known functional significance) and in vitro sensitivity tests to artemisinins and other antimalarials. Additional blood samples will be used for measuring plasma organic acid biomarkers of severe falciparum malaria measured by mass spectrometry. Difference in the kinetics of these acids will be an additional endpoint. Difference in the transcriptome of p. falciparum will be assessed by RNA measurements at baseline and 3 timepoints during treatment.
The proposed sites in Vietnam and Cambodia have been chosen based on the prevalence of artemisinin resistant falciparum malaria, incidence of severe malaria and local experience in participating in clinical trials.
Interim analysis:
To ensure timely recognition of the effect of artemisinin resistance on the outcome in malaria treated with parenteral artesunate, an interim analysis will be performed after the inclusion of 60 patients or one malaria transmission season (whatever comes first). An independent Data Safety Board will assess whether the difference in outcome between infections with artemisinin resistant versus sensitive strains warrants early termination and reporting of the study.
Typ studiów
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Opis
Inclusion Criteria:
- Male or female, aged over 6 months old
Acute severe P. falciparum malaria or another indication to treat with IV artesunate. Defined as one or more of the following, occurring in the absence of an identified alternative cause, and in the presence of P. falciparum asexual parasitaemia:
- Prostration OR obtundation
- BCS<3 (preverbal children) or GCS<11 (adults)
- Convulsion in last 24 hours
- Suspected acidosis, manifesting as acidotic breathing
- Respiratory distress manifesting clinically (nasal flaring/indrawing) or oxygen saturation <92% or respiratory rate >30/min
- History of anuria
- Jaundice and/or hemoglobinuria
- Hemoglobin <7 g/dl or hematocrit <20%
- Significant bleeding including recurrent or prolonged bleeding from nose gums or venipuncture sites; hematemesis or melena
- Shock defined as systolic blood pressure <70 mm Hg (children) OR <80 mm Hg (adults)
- P. falciparum parasitaemia >10%
Indication for parenteral antimalarial treatment (as assessed by clinician) other than nausea and vomiting. These may include laboratory findings such as:
- Creatinine >2.5 mg/dL (>220uM/L) or blood urea >56mg/dL (>20 mM/L)
- Glucose <4.0 mmol/L (<72mg/dL)
- Bilirubin > 3 mg/dL (>50uM/L)
- Hemoglobin <7g/dL or Hematocrit <20%
- P. falciparum parasitaemia >4%
- Venous plasma lactate >5 mM, Base deficit of >8meq/L or bicarbonate <15mM
- Written informed consent or consent by locally accepted representative in the case of patients rendered incapable of providing consent due to illness
Exclusion Criteria:
- History of 2 or more doses of parenteral antimalarial treatment in the previous 24 hours
- History of allergy or known contraindication to artemisinins
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
Kohorty i interwencje
Grupa / Kohorta |
Interwencja / Leczenie |
---|---|
Study subjects
Patients admitted with malaria, caused by Plasmodium falciparum, treated with parenteral artesunate.
|
Intravenous Artesunate 2.4 mg/kg
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Absolute reduction of lactate
Ramy czasowe: 12 hours
|
Absolute reduction of lactate at 12 hours after the first artesunate treat-ment compared to baseline.
|
12 hours
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Time needed until a plasma lactate concentration <2 mmol/L
Ramy czasowe: 42 days
|
42 days
|
|
Change in Glasgow Coma Score (GCS) or Blantyre Coma Score (BCS)
Ramy czasowe: 12 hours
|
at 12 hours after initial treatment and coma recovery time defined as GCS>10 or BCS>3 and GCS=15 and BCS=5
|
12 hours
|
Base excess clearance after 12 hours
Ramy czasowe: 42 days
|
Base excess clearance after 12 hours as proportion of the base excess at presentation
|
42 days
|
Time until a base excess concentration ≥ minus 2 mmol/L
Ramy czasowe: 42 days
|
42 days
|
|
Time to resuming the ability to sit, eat, drink, stand unsupported and walk
Ramy czasowe: 42 days
|
42 days
|
|
The parasite clearance half-life
Ramy czasowe: 48 hours
|
48 hours
|
|
The parasite clearance ratios at H28 and H48 compared to parasite count on admission
Ramy czasowe: 48 hours
|
48 hours
|
|
The parasite clearance time for parasite count to fall to 50%, 90% and 99% of initial parasite density
Ramy czasowe: 7 days
|
7 days
|
|
Differences in transcriptome patterns between artemisinin resistant parasites and artemisinin sensitive parasites at baseline
Ramy czasowe: H0
|
H0
|
|
Differences in transcriptome patterns between artemisinin resistant parasites and artemisinin sensitive parasites at H6
Ramy czasowe: H6
|
H6
|
|
Differences in transcriptome patterns between artemisinin resistant parasites and artemisinin sensitive parasites at H12
Ramy czasowe: H12
|
H12
|
|
Differences in transcriptome patterns between artemisinin resistant parasites and artemisinin sensitive parasites at H48
Ramy czasowe: H48
|
H48
|
|
Time until resolution of fever
Ramy czasowe: 14 days
|
(time until tympanic temperature first <37.5 Celsius and below 37.5C for 24 h)
|
14 days
|
Proportion of patients developing new malaria
Ramy czasowe: 42 days
|
Proportion of patients developing new malaria severity signs as defined in the 2014 WHO severe malaria guidelines
|
42 days
|
Proportion of patients developing new neurological signs assessed by neurological examination during hospitalization
Ramy czasowe: 42 days
|
42 days
|
|
Prevalence of neurological sequelae assessed by neurological examination at discharge
Ramy czasowe: 42 days
|
42 days
|
|
Prevalence of neurological sequelae assessed by neurological examination at day 7
Ramy czasowe: 7 days
|
7 days
|
|
Prevalence of neurological sequelae assessed by neurologicalexamination at day 14
Ramy czasowe: 14 days
|
14 days
|
|
Prevalence of neurological sequelae assessed by neurological examination at day 28 if day 14 is abnormal
Ramy czasowe: 28 days
|
28 days
|
|
Prevalence of neurological sequelae assessed by neurological examination at day 42 if day 28 is abnormal
Ramy czasowe: 42 days
|
42 days
|
|
Severity of neurological sequelae assessed by neurological examination at discharge
Ramy czasowe: 42 days
|
42 days
|
|
Severity of neurological sequelae assessed by neurological examination at day 7
Ramy czasowe: 7 days
|
7 days
|
|
Severity of neurological sequelae assessed by neurological examination at day 14
Ramy czasowe: 14 days
|
14 days
|
|
Severity of neurological sequelae assessed by neurological examination at day 28 if day 14 is abnormal
Ramy czasowe: 28 days
|
28 days
|
|
Severity of neurological sequelae assessed by neurological examination at day 42 if day 28 is abnormal
Ramy czasowe: 42 days
|
42 days
|
|
Proportion treated with quinine
Ramy czasowe: 42 days
|
as a rescue treatment, antibiotics, blood products, anticonvulsants, renal replacement therapy, mechanical ventilation therapy, vasopressive drugs and oxygen therapy
|
42 days
|
In hospital mortality
Ramy czasowe: 42 days
|
42 days
|
|
Day 7, 14 hemoglobin or hematocrit levels
Ramy czasowe: 42 days
|
and in addition at day 28 and 42 if abnormal at day 14 or day 28 respectively
|
42 days
|
Creatinine levels daily
Ramy czasowe: 42 days
|
during the first four days and thereafter on day 7 and 14 and in addition on day 28 and 42 if abnormal on day 14 or day 28 respectively
|
42 days
|
Bilirubin, Alanine transaminase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase levels daily
Ramy czasowe: 42 days
|
during the first four days and thereafter on day 7, 14 and in addition on day 28 and 42 if abnormal on day 14 or 28 respectively
|
42 days
|
Plasma biomarkers of severe (artemisinin resistant) malaria
Ramy czasowe: 42 days
|
42 days
|
|
outcome of pregnancy during hospitalization
Ramy czasowe: 42 days
|
If pregnant
|
42 days
|
Time until discharge
Ramy czasowe: 42 days
|
42 days
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: Prof. Arjen M Dondorp, MD, Mahidol Oxford Research Unit (MORU)
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Infekcje
- Choroby przenoszone przez wektory
- Choroby pasożytnicze
- Infekcje pierwotniakowe
- Malaria
- Środki przeciwinfekcyjne
- Środki przeciwwirusowe
- Środki przeciwnowotworowe
- Środki przeciwpierwotniacze
- Środki przeciwpasożytnicze
- Leki przeciwmalaryczne
- Środki przeciw robakom
- Schistosomicydy
- Środki przeciw robakom płazicielskim
- Artesunat
Inne numery identyfikacyjne badania
- BAKMAL1504
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst i inni współpracownicyRekrutacyjnyMalaria Plasmodium Falciparum | Malaria Plasmodium VivaxLaotańska Republika Ludowo-Demokratyczna
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanZakończonyVivax Malaria | Nieskomplikowana malaria FalciparumAfganistan
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaZakończonyMalaria Plasmodium Falciparum | Malaria Plasmodium VivaxPeru
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... i inni współpracownicyZakończonyMalaria | Vivax Malaria | Falciparum MalariaEtiopia, Bangladesz, Indonezja
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...ZakończonyMalaria Plasmodium Falciparum | Malaria Plasmodium VivaxIndonezja
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...ZakończonyVivax Malaria | Falciparum MalariaIndonezja
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... i inni współpracownicyZakończonyMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...ZakończonyVivax Malaria | Falciparum MalariaIndonezja
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst i inni współpracownicyRekrutacyjnyMalaria Plasmodium Falciparum | Malaria Plasmodium VivaxTajlandia
-
U.S. Army Office of the Surgeon GeneralU.S. Army Medical Research and Development Command; Military Infectious Diseases...ZakończonyFalciparum Malaria | Nieskomplikowana malariaKenia, Tajlandia